The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma. - Archive ouverte HAL Access content directly
Journal Articles Retrovirology Year : 2013

The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.

(1) , (2) , (3) , (4) , (3) , (5) , (6) , (7) , (1) , (1) , (3) , (3) , (3) , (1) , (3) , (8) , (9) , (10) , (3) , (3)
1
2
3
4
5
6
7
8
9
10
Ghada Kchour
  • Function : Author
  • PersonId : 946112
Sa Rahim Rezaee
  • Function : Author
  • PersonId : 946113
Akram Ghantous
  • Function : Author
  • PersonId : 946115
Mahdi Tarhini
  • Function : Author
  • PersonId : 946117
Hiba El Hajj
  • Function : Author
  • PersonId : 946119
Fadwa Berry
  • Function : Author
  • PersonId : 946120
Mohamad Mortada
  • Function : Author
  • PersonId : 946121
Mohamad Ezzedine
  • Function : Author
  • PersonId : 946125
Hugues de Thé

Abstract

BACKGROUND: HTLV-I associated adult T-cell leukemia/lymphoma (ATL) carries a dismal prognosis due to chemo-resistance and immuno-compromised micro-environment. The combination of zidovudine and interferon-alpha (IFN) significantly improved survival in ATL. Promising results were reported by adding arsenic trioxide to zidovudine and IFN. RESULTS: Here we assessed Th1/Th2/Treg cytokine gene expression profiles in 16 ATL patients before and 30 days after treatment with arsenic/IFN/zidovudine, in comparison with HTLV-I healthy carriers and sero-negative blood donors. ATL patients at diagnosis displayed a Treg/Th2 cytokine profile with significantly elevated transcript levels of Foxp3, interleukin-10 (IL-10), and IL-4 and had a reduced Th1 profile evidenced by decreased transcript levels of interferon-γ (IFN-γ) and IL-2. Most patients (15/16) responded, with CD4+CD25+ cells significantly decreasing after therapy, paralleled by decreases in Foxp3 transcript. Importantly, arsenic/IFN/zidovudine therapy sharply diminished IL-10 transcript and serum levels concomittant with decrease in IL-4 and increases in IFN-γ and IL-2 mRNA, whether or not values were adjusted to the percentage of CD4+CD25+ cells. Finally, IL-10 transcript level negatively correlated with clinical response at Day 30. CONCLUSIONS: The observed shift from a Treg/Th2 phenotype before treatment toward a Th1 phenotype after treatment with arsenic/IFN/zidovudine may play an important role in restoring an immuno-competent micro-environment, which enhances the eradication of ATL cells and the prevention of opportunistic infections.
Fichier principal
Vignette du fichier
1742-4690-10-91.pdf (687.15 Ko) Télécharger le fichier
Vignette du fichier
1742-4690-10-91.xml (130.67 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00868737 , version 1 (01-10-2013)

Identifiers

Cite

Ghada Kchour, Sa Rahim Rezaee, Reza Farid, Akram Ghantous, Houshang Rafatpanah, et al.. The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.. Retrovirology, 2013, 10 (1), pp.91. ⟨10.1186/1742-4690-10-91⟩. ⟨inserm-00868737⟩
336 View
320 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More